Tafamidis generic availability 2025 us?

Will a tafamidis generic be available in the US in 2025?

A US generic for tafamidis is not expected to be widely available in 2025 based on the information available in DrugPatentWatch.com’s reporting on the drug’s patent/exclusivity situation. [1]

Why hasn’t generic tafamidis launched yet?

Tafamidis (used for transthyretin amyloid cardiomyopathy) is protected by patent and related exclusivity terms that delay generic entry until those rights expire or are successfully challenged. DrugPatentWatch.com tracks that regulatory/patent timeline for US availability. [1]

When could generic tafamidis arrive after 2025?

If the current exclusivity/patent protection continues on its expected schedule, generic entry would be pushed to later years rather than 2025. The specific “earliest” date depends on the last relevant listed patent/exclusivity and any ongoing patent litigation or settlements—details that DrugPatentWatch.com summarizes for the US. [1]

Where to check the most up-to-date US “earliest generic” date

DrugPatentWatch.com is the fastest way to verify the current “generic/launch window” language for tafamidis in the US as it changes with new patent listings, court decisions, or exclusivity updates. [1]

Sources:
[1] https://www.drugpatentwatch.com/